Logo image of VERA

VERA THERAPEUTICS INC (VERA) Stock Price, Quote, News and Overview

NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD

22.7  -7.93 (-25.89%)

After market: 22.6 -0.1 (-0.44%)

VERA Quote, Performance and Key Statistics

VERA THERAPEUTICS INC

NASDAQ:VERA (6/6/2025, 9:56:07 PM)

After market: 22.6 -0.1 (-0.44%)

22.7

-7.93 (-25.89%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High51.61
52 Week Low18.53
Market Cap1.45B
Shares63.77M
Float59.93M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/bmo
IPO05-14 2021-05-14


VERA short term performance overview.The bars show the price performance of VERA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

VERA long term performance overview.The bars show the price performance of VERA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60

The current stock price of VERA is 22.7 USD. In the past month the price increased by 3.04%. In the past year, price decreased by -41.04%.

VERA THERAPEUTICS INC / VERA Daily stock chart

VERA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.48 335.32B
AMGN AMGEN INC 13.99 156.11B
GILD GILEAD SCIENCES INC 14.53 139.89B
VRTX VERTEX PHARMACEUTICALS INC N/A 115.69B
REGN REGENERON PHARMACEUTICALS 11.13 53.25B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.23B
ARGX ARGENX SE - ADR 101.9 35.78B
ONC BEONE MEDICINES LTD-ADR 6.54 27.66B
BNTX BIONTECH SE-ADR N/A 26.08B
NTRA NATERA INC N/A 22.36B
BIIB BIOGEN INC 8.42 19.51B
SMMT SUMMIT THERAPEUTICS INC N/A 15.29B

About VERA

Company Profile

VERA logo image Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 112 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.

Company Info

VERA THERAPEUTICS INC

2000 Sierra Point Parkway, Suite 1200

Brisbane California CALIFORNIA 14623 US

CEO: Marshall Fordyce

Employees: 72

VERA Company Website

VERA Investor Relations

Phone: 16507700077

VERA THERAPEUTICS INC / VERA FAQ

What is the stock price of VERA THERAPEUTICS INC today?

The current stock price of VERA is 22.7 USD. The price decreased by -25.89% in the last trading session.


What is the ticker symbol for VERA THERAPEUTICS INC stock?

The exchange symbol of VERA THERAPEUTICS INC is VERA and it is listed on the Nasdaq exchange.


On which exchange is VERA stock listed?

VERA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VERA THERAPEUTICS INC stock?

19 analysts have analysed VERA and the average price target is 67.25 USD. This implies a price increase of 196.24% is expected in the next year compared to the current price of 22.7. Check the VERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VERA THERAPEUTICS INC worth?

VERA THERAPEUTICS INC (VERA) has a market capitalization of 1.45B USD. This makes VERA a Small Cap stock.


How many employees does VERA THERAPEUTICS INC have?

VERA THERAPEUTICS INC (VERA) currently has 72 employees.


What are the support and resistance levels for VERA THERAPEUTICS INC (VERA) stock?

VERA THERAPEUTICS INC (VERA) has a support level at 18.86 and a resistance level at 22.71. Check the full technical report for a detailed analysis of VERA support and resistance levels.


Should I buy VERA THERAPEUTICS INC (VERA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VERA THERAPEUTICS INC (VERA) stock pay dividends?

VERA does not pay a dividend.


When does VERA THERAPEUTICS INC (VERA) report earnings?

VERA THERAPEUTICS INC (VERA) will report earnings on 2025-08-06, before the market open.


What is the Price/Earnings (PE) ratio of VERA THERAPEUTICS INC (VERA)?

VERA THERAPEUTICS INC (VERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).


What is the Short Interest ratio of VERA THERAPEUTICS INC (VERA) stock?

The outstanding short interest for VERA THERAPEUTICS INC (VERA) is 11.8% of its float. Check the ownership tab for more information on the VERA short interest.


VERA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to VERA. When comparing the yearly performance of all stocks, VERA is a bad performer in the overall market: 90.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VERA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VERA. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VERA Financial Highlights

Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -3. The EPS decreased by -44.93% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -28.76%
ROE -32.8%
Debt/Equity 0.1
Chartmill High Growth Momentum
EPS Q2Q%-44.64%
Sales Q2Q%N/A
EPS 1Y (TTM)-44.93%
Revenue 1Y (TTM)N/A

VERA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 84% to VERA. The Buy consensus is the average rating of analysts ratings from 19 analysts.


Ownership
Inst Owners108.09%
Ins Owners2.74%
Short Float %11.8%
Short Ratio5.03
Analysts
Analysts84.21
Price Target67.25 (196.26%)
EPS Next Y-21.39%
Revenue Next YearN/A